Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022
September 23, 2022 at 01:34 am IST
Share
Curis, Inc. announced that on September 19, 2022, Lori A. Kunkel, M.D. submitted her written resignation from the Board of Directors of the Company effective September 30, 2022. At the time of her resignation, Dr. Kunkel served as a member of the Board's Nominating and Corporate Governance Committee and as chair of the Board's Clinical Program Committee. The company believes that Dr. Kunkel resigned due to a fundamental difference in belief on company operations which, therefore, led her to the professional preference to no longer serve as a director, as discussed in the Resignation Letter.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
CURIS, INC. 
